ACT Brief: Remote Monitoring and Early Intervention, NAMs Replace Animal Testing, and Glass Box Clinical Intelligence

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In part two of his video interview, Mohammed Saeed, MD, PhD, chief medical officer of Solera Health, discussed how continuous remote monitoring allows caregivers to detect early warning signs of deterioration at home. Early detection enables timely interventions — medication adjustments or escalation — before patients require hospitalization or emergency care, fundamentally changing the cadence of care management between clinic visits.
• The FDA released draft guidance on validating new approach methodologies (NAMs) as alternatives to animal testing in preclinical drug development. The framework establishes four core validation principles — context of use, human biological relevance, technical characterization, and fit-for-purpose — allowing sponsors to incorporate NAMs into IND-enabling programs. The guidance clarifies that full validation is not always required; fit-for-purpose NAMs may satisfy regulatory requirements within a broader weight of evidence.
• In a new interview from Pharmaceutical Executive, Jiang Li, CEO of Vivalink, discussed the shift from "black box" to "glass box" clinical intelligence in decentralized trials. Transparent, timestamped raw data — such as physiological signals — paired with synthesized insights enable clinicians to verify underlying physiology and understand patient trends. Continuous monitoring captures 20 to 30 times more data coverage than clinic snapshots, though successful implementation requires robust logistics and strong patient adherence to sensors across multiple countries and sites.

That's all for today's ACT Brief. Join us tomorrow more updates shaping clinical operations and drug development. Thanks for listening.